Results 171 to 180 of about 92,680 (316)

Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second‐Line (The GOING Trial)

open access: yesAlimentary Pharmacology &Therapeutics, Volume 63, Issue 7, Page 955-966, April 2026.
In the phase I/IIa GOING trial, an add‐on strategy with regorafenib followed by nivolumab showed a manageable safety profile and meaningful clinical activity in second‐line hepatocellular carcinoma, with a median overall survival of 25 months and 45% three‐year survival in sorafenib‐experienced patients.
Marco Sanduzzi‐Zamparelli   +24 more
wiley   +1 more source

Do Voluntary Pollution Reduction Programs (VPRs) Spur Innovation in Environmental Technology [PDF]

open access: yes
In the context of the EPA's 33/50 program, we study whether a VPR can prompt firms to develop new environmental technologies that yield future emission reduction benefits.
Carrion-Flores, Carmen E.   +2 more
core   +1 more source

Are carrion resources as scarce as we think

open access: green, 2020
Madison A. Laprise   +2 more
openalex   +1 more source

Distribution, scale, and drivers of mass mortality events in Europe's freshwater bivalves

open access: yesConservation Biology, Volume 40, Issue 2, April 2026.
Abstract Mass mortality events (MMEs) are decimating populations and compromising key ecosystem functions around the globe. One taxon particularly vulnerable to MMEs is freshwater bivalve mollusks. This group has important ecosystem engineering capacities and includes highly threatened and highly invasive taxa.
Daniel A. Cossey   +39 more
wiley   +1 more source

Early Oral Immunotherapy With Pasteurized Egg White in Egg-Allergic Children Under 2 Years of Age. [PDF]

open access: yesClin Transl Allergy
Carrión Sari SK   +3 more
europepmc   +1 more source

Exposure to Antipsychotics in Youths at Clinical High Risk for Psychosis: Low VS High Doses and Their Relevance for Clinical Outcomes

open access: yesEarly Intervention in Psychiatry, Volume 20, Issue 4, April 2026.
ABSTRACT Introduction Predicting prognosis in subjects at Clinical High Risk for Psychosis (CHR‐P) is still challenging. In particular, there are some disregarded factors such as ongoing Antipsychotic (AP) treatment that potentially induce method errors and research bias.
Lorenzo Pelizza   +9 more
wiley   +1 more source

Carrion Decomposition

open access: yes, 2019
Barton, Philip, Bump, J. K
openaire   +2 more sources

Home - About - Disclaimer - Privacy